Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
In: SomanJ, Lonl S, Rosenthal H, Resnk S, Kakhnshv Waller EK. A randomed, placebo-controlled trl of subcutaneous admtratn of GM-CSF as a vacce adjuvant: effect on cellular and humoral mune responses. Vacce. 2002 Dec 13;21(3-4):221-30. do 10.1016/s0264-410x(02)00463-2. Gbert PB, Ch YL, Allen M, Lawrence DN, Chapdu C, rael H, Holman D, Keefer MC, Wolff M, Frey SE; N H Vacce Trls Network. Long-term safety analys of prevente H-1 vacces evaluated AS vacce evaluatn group N-sponsored Phase and clal trls. Vacce. 2003 Jun 20;21(21-22):2933-47. do 10.1016/s0264-410x(03)00158-0. A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants
Online
report
Titel: |
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
|
---|---|
Link: | |
Quelle: | SomanJ, Lonl S, Rosenthal H, Resnk S, Kakhnshv Waller EK. A randomed, placebo-controlled trl of subcutaneous admtratn of GM-CSF as a vacce adjuvant: effect on cellular and humoral mune responses. Vacce. 2002 Dec 13;21(3-4):221-30. do 10.1016/s0264-410x(02)00463-2. Gbert PB, Ch YL, Allen M, Lawrence DN, Chapdu C, rael H, Holman D, Keefer MC, Wolff M, Frey SE; N H Vacce Trls Network. Long-term safety analys of prevente H-1 vacces evaluated AS vacce evaluatn group N-sponsored Phase and clal trls. Vacce. 2003 Jun 20;21(21-22):2933-47. do 10.1016/s0264-410x(03)00158-0. A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants |
Medientyp: | report |
Sonstiges: |
|